Phase 1/2/3

A novel AI-designed drug that can cross the formidable blood-brain barrier has entered U.S. trials, targeting some of the deadliest brain tumors.

With $9M in new funding, Trellis Bioscience advances a novel antibody that shatters bacterial defenses, offering hope for devastating joint infections.

Beyond GLP-1, Boehringer Ingelheim’s new drug targets the brain's hunger signals, a calculated move in the high-stakes race for obesity treatment.

Kura Oncology's upcoming kidney cancer data is just the tip of the iceberg. A closer look reveals a strategic play to make darlifarnib a universal partner drug.

A Norwegian biotech has dosed its first patient with a novel TCR-NK therapy, a potential breakthrough in delivering scalable, precise treatment for solid tumors.

Delonix Bioworks is running parallel trials in China and Australia for its MenB vaccine, a strategic gambit that could disrupt a billion-dollar market.

A Swiss biotech's oral drug just showed it can cross into the human brain and alter its activity, a key de-risking step in a high-stakes pivot.

Serina Therapeutics' Parkinson's drug SER-252 advances, but the real story is its POZ Platform, a technology that could reshape drug delivery.

Preclinical data shows GLIX1 can make PARP inhibitors effective in previously unresponsive tumors, a potential game-changer for 50% of ovarian cancer patients.

HMNC Brain Health's new oral ketamine shows promise by minimizing side effects, but an unmet endpoint raises questions. Is this the key to at-home TRD care?

With €33M in new funding, Cyllene Therapeutics is advancing a novel gene therapy using HSV-1 vectors. Could this be the one-shot cure for millions?

Immunomic Therapeutics begins human trials for ITI-9001, an saRNA vaccine aiming to rewrite the immune response to Japanese cedar pollen allergy.

NKGen Biotech signals a strategic pivot to Asia, leveraging its novel NK cell therapy, troculeucel, to tap into China's new, accelerated biotech pathways.

A new study for CRENESSITY could revolutionize care for infants with classic congenital adrenal hyperplasia, shifting the treatment paradigm and solidifying market leadership.

For women with resistant ovarian cancer, options are few. A new drug, NTB-928, uses a dual-key design to unlock the immune system against tumors.

Artelo Biosciences uses advanced analytics to link its lead drug to a core disease pathway, a strategic move to de-risk development and attract major partners.

New Phase 1 data suggests vamorolone delivers potent anti-inflammatory effects without the severe immunosuppression of traditional steroids at clinical doses.

Interim data for Pasithea Therapeutics' PAS-004 shows durable activity and superior safety, offering a new strategy for patients who have run out of options.

Biotech firm R1 Therapeutics forms a star-studded advisory board to guide its promising kidney disease drug, AP306, into crucial Phase 2b trials.

Cytonics completes a key safety trial for its novel osteoarthritis drug, CYT-108. But the real story is a masterclass in strategic innovation.